PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Core Viewpoint - PDS Biotechnology Corporation has announced a registered direct offering of 7,330,121 shares of common stock and warrants, aiming to raise approximately $11 million for research and development and general corporate purposes [1][2]. Group 1: Offering Details - The offering includes 7,330,121 shares priced at $1.50 for institutional investors and $1.66 for certain directors, with warrants exercisable at $1.50 per share [1]. - The gross proceeds from the offering are expected to be around $11 million, with an additional potential $11 million from the exercise of warrants [2]. - The closing of the offering is anticipated on or about February 28, 2025, pending customary closing conditions [2]. Group 2: Company Overview - PDS Biotechnology is a late-stage immunotherapy company focused on enhancing the immune system's ability to target and eliminate cancers [5]. - The company plans to initiate a pivotal clinical trial for its lead program targeting advanced HPV16-positive head and neck squamous cell cancers [5]. - The lead investigational immunotherapy, Versamune® HPV, is being developed in combination with a standard immune checkpoint inhibitor and a triple combination including PDS01ADC [5].